Avita Medical Inc.
RCEL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RCEL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RCEL
Avita Medical Inc. (RCEL) is a regenerative medicine company focused on developing and commercializing its RECELL System for burn, trauma, and vitiligo indications, with a recent financial profile showing $21.5M in revenue but ongoing net losses and negative equity.
Key risk: Liquidity risk
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 2 clinical trials for Avita Medical Inc..
Avita Medical Inc. (RCEL) is a regenerative medicine company focused on developing and commercializing its RECELL System for burn, trauma, and vitiligo indications, with a recent financial profile showing $21.5M in revenue but ongoing net losses and negative equity.
- Cash & equivalents of $9.1M as of 2026-06-30 [sec].
- Total revenue of $21.5M for the period ending 2026-06-30 [sec].
- Net loss of $7.7M for the period ending 2026-06-30 [sec].
- Shareholders' equity of -$16.6M as of 2026-06-30 [sec].
- Total debt of $46.7M as of 2026-06-30 [sec].
What works
- The company has a clear product portfolio expansion strategy, including clinical development of the RECELL System for pediatric burns, trauma injuries, and vitiligo [sec · filed 2020-08-27].
- The Board actively oversees risk management, including product portfolio expansion and regulatory acceptance, indicating structured governance [sec · filed 2026-04-22].
- The company has a compensation framework designed to attract and retain high-caliber executives, which may support long-term execution [sec · filed 2020-08-27].
What to weigh
- The company has experienced significant losses and expects to continue losses for the foreseeable future, with no guarantee of achieving profitability [sec · filed 2020-08-27].
- Negative shareholders' equity of -$16.6M as of 2026-06-30 indicates a weak equity base [sec].
- High debt of $46.7M relative to cash of $9.1M as of 2026-06-30 raises liquidity concerns [sec].
- The company faces risks from competition, regulatory delays, and potential failure to manage growth effectively [sec · filed 2020-08-27].
From the filings
Quoted directly from source documents.
The company has experienced significant losses and expects to continue losses for the foreseeable future.
“We have experienced significant losses, expect losses to continue for the foreseeable future and may never achieve or maintain profitabi”
SEC filings · August 27, 2020
The Board oversees risk management including product portfolio expansion and regulatory acceptance.
“Specific areas of enterprise risk which are regularly considered at Board meetings include: product portfolio expansion, acceptance by regulatory authorities of th”
SEC filings · April 22, 2026
The company has a compensation framework to attract and retain high-caliber executives.
“Provide competitive rewards to attract and retain high caliber executives;”
SEC filings · August 27, 2020
The company is developing the RECELL System for pediatric burns, trauma injuries, and vitiligo.
“clinical development of our RECELL System to such areas as pediatric burns, trauma injuries and vitiligo;”
SEC filings · August 27, 2020
Risks & what to watch (4)›
Key risks
- Liquidity risk — Cash of $9.1M vs. debt of $46.7M as of 2026-06-30; negative equity of -$16.6M [sec].
- Profitability uncertainty — Continued net losses of $7.7M for the period ending 2026-06-30; no guarantee of achieving profitability [sec].
- Regulatory and competitive risks — Delays in regulatory approvals and competition from existing standard of care could harm commercialization [sec · filed 2020-08-27].
- Growth management risk — Failure to manage growth effectively could disrupt business; reliance on large-scale manufacturing [sec · filed 2020-08-27].
What to watch
- Monitor cash burn rate and any additional financing activities given low cash relative to debt [sec].
- Watch for updates on clinical development of RECELL System for pediatric burns, trauma, and vitiligo [sec · filed 2020-08-27].
- Track regulatory decisions and approvals that could impact product commercialization [sec · filed 2020-08-27].
- Observe revenue growth trajectory and progress toward profitability [sec].
Sources: SEC filings · Generated August 24, 2026 · How we verify sources →
Run Avita Medical Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Avita Medical Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
13.9 months
OCF -$3M · Net income -$8M
Lead: Approved
4 candidates
No upcoming catalysts tracked
12 buys · 0 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
78
Total value held
$189.8M
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 41,510,995 | $156.5M |
| vanguard capital management llc | 2,670,304 | $9.9M |
| eversource wealth advisors, llc | 102,535 | $9.7M |
| blackrock, inc. | 1,133,126 | $4.2M |
| geode capital management, llc | 542,974 | $2.0M |
| state street corp | 429,022 | $1.6M |
| vanguard fiduciary trust co | 193,436 | $716K |
| northern trust corp | 183,181 | $678K |
| morgan stanley | 157,621 | $583K |
| goldman sachs group inc | 99,845 | $369K |
Showing top 10 of 78 institutional holders of Avita Medical Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 11.2%
- Days to cover
- 15.7
- Shares short
- 3,417,316
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RCEL short interestGovernance
Frequently asked questions
What is the AI investment thesis for Avita Medical Inc.?
Avita Medical Inc. (RCEL) is a regenerative medicine company focused on developing and commercializing its RECELL System for burn, trauma, and vitiligo indications, with a recent financial profile showing $21.5M in revenue but ongoing net losses and negative equity.
What is Avita Medical Inc.'s lead drug candidate?
Avita Medical Inc.'s most advanced tracked candidate is cohealyx (Approved) for Full-thickness wounds and burns.
Who is the CEO of Avita Medical Inc.?
Mr. Cary G. Vance is the chief executive officer of Avita Medical Inc. (RCEL).
Where is Avita Medical Inc. headquartered?
Avita Medical Inc. (RCEL) is headquartered in Valencia, CA, United States.
What therapeutic areas does Avita Medical Inc. focus on?
Avita Medical Inc. develops therapies across Immunology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.